Have a feature idea you'd love to see implemented?
Let us know!
STOK Stoke Therapeutics Inc
Price (delayed)
$11.32
Market cap
$599.59M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.1
Enterprise value
$449.5M
Stoke Therapeutics, is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines. Using the company's proprietary TANGO (Targeted Augmentation of
Highlights
The revenue has soared by 81% YoY and by 10% from the previous quarter
The company's gross profit has surged by 81% YoY and by 10% QoQ
Stoke Therapeutics's equity has increased by 34% YoY but it has decreased by 4.4% from the previous quarter
Stoke Therapeutics's quick ratio has decreased by 44% YoY and by 24% from the previous quarter
Key stats
What are the main financial stats of STOK
Market
Valuations
Earnings
Shares outstanding
52.97M
Market cap
$599.59M
Enterprise value
$449.5M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.57
Price to sales (P/S)
38.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.85
Revenue
$16.74M
Gross profit
$16.74M
Net income
-$105.46M
EBIT
-$117.71M
EBITDA
-$113.16M
Free cash flow
-$84.7M
Per share
Balance sheet
Liquidity
EPS
-$2.1
EPS diluted
-$2.1
Free cash flow per share
-$1.5
Book value per share
$4.41
Revenue per share
$0.3
TBVPS
$5.21
Total assets
$293.32M
Total liabilities
$61.21M
Debt
$0
Equity
$232.11M
Working capital
$203.75M
Debt to equity
0
Current ratio
5.09
Quick ratio
4.8
Net debt/EBITDA
1.33
Margins
Efficiency
Dividend
EBITDA margin
-675.9%
Gross margin
100%
Net margin
-629.9%
Operating margin
-700.6%
Return on assets
-40.8%
Return on equity
-54.4%
Return on invested capital
-295%
Return on capital employed
-48.3%
Return on sales
-703%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
STOK stock price
How has the Stoke Therapeutics stock price performed over time
Intraday
-2.5%
1 week
-6.45%
1 month
-0.96%
1 year
112.38%
YTD
115.21%
QTD
-7.89%
Financial performance
How have Stoke Therapeutics's revenue and profit performed over time
Revenue
$16.74M
Gross profit
$16.74M
Operating income
-$117.3M
Net income
-$105.46M
Gross margin
100%
Net margin
-629.9%
The revenue has soared by 81% YoY and by 10% from the previous quarter
The company's gross profit has surged by 81% YoY and by 10% QoQ
STOK's net margin is up by 44% year-on-year and by 8% since the previous quarter
The operating margin has grown by 42% YoY and by 7% from the previous quarter
Growth
What is Stoke Therapeutics's growth rate over time
Valuation
What is Stoke Therapeutics stock price valuation
P/E
N/A
P/B
2.57
P/S
38.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.85
The EPS has grown by 13% YoY and by 3.7% from the previous quarter
Stoke Therapeutics's equity has increased by 34% YoY but it has decreased by 4.4% from the previous quarter
The P/B is 27% below the 5-year quarterly average of 3.5 and 11% below the last 4 quarters average of 2.9
The revenue has soared by 81% YoY and by 10% from the previous quarter
The price to sales (P/S) is 23% lower than the last 4 quarters average of 49.3
Efficiency
How efficient is Stoke Therapeutics business performance
STOK's return on invested capital has dropped by 55% year-on-year but it is up by 42% since the previous quarter
The ROS has grown by 42% YoY and by 7% from the previous quarter
The ROE has increased by 6% since the previous quarter
STOK's ROA is up by 3.3% from the previous quarter but it is down by 2% YoY
Dividends
What is STOK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for STOK.
Financial health
How did Stoke Therapeutics financials performed over time
Stoke Therapeutics's quick ratio has decreased by 44% YoY and by 24% from the previous quarter
STOK's current ratio is down by 44% year-on-year and by 24% since the previous quarter
STOK's debt is 100% smaller than its equity
Stoke Therapeutics's equity has increased by 34% YoY but it has decreased by 4.4% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.